Delivery Order SPE2DB22D3401-SPE2DB25FT6BP
- Not listed
- The Defense Logistics Agency awarded a $32,614.21 delivery order to AmerisourceBergen Drug Corp for Skyrizi 150 mg/ml pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency awarded a $279,751.97 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 150 MG/ML in pen/milliliter formulation. This is a firm fixed price contract with no set-aside designation, executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is set to be completed by September 9, 2025, with fulfillment occurring at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body applicator units. The contract is firm fixed price with no set-aside designation and carries an ultimate completion date of September 11, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is set to complete by September 18, 2025, with performance executed from AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This delivery order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $11,972.91 delivery order on August 19, 2025, for SKYRIZI 150 MG/ML pen/mL, a prescription biologic medication. This firm fixed price, competitively awarded contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL in pen form, valued at $24,893.20 under a firm fixed-price contract awarded on August 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion master contract running through December 2026 that serves as a comprehensive global pharmaceutical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for SKYRIZI 150 mg/ml pen medication. This firm fixed-price contract, valued at $35,400.44, represents a non-competitive set-aside delivery order with an ultimate completion date of July 24, 2025. The award leverages AmerisourceBergen's established position within the federal pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $24,512.38 to AmerisourceBergen Drug Corp for the supply of Skyrizi 150 mg/mL pen injections. This competitively awarded, firm fixed-price contract was issued on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order with no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded a delivery order valued at $15,346.24 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pharmaceutical product on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed at the contractor's Conshohocken, Pennsylvania facility. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injection delivery systems. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by October 1, 2025. The contract represents a fulfillment of pharmaceutical supply needs through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT6BPDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Skyrizi 600 mg/10 mL vials with a ceiling value of $24,478.76 and firm fixed pricing. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor in the federal medical supply chain, particularly for military and veteran healthcare systems under the DLA's Medical Supply Chain program. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical procurement requirements, from brand-name specialty medications to generic drugs, vaccines, and medical devices. This delivery order for Skyrizi, a biologic immunosuppressant medication, exemplifies the company's role in supplying specialized pharmaceutical products to support Defense Health Agency operations and other government healthcare systems through the comprehensive global pharmaceutical support vehicle established by DLA Troop Support.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.5k | 9/9/25 |